Table 3.
Risks of Adverse Clinical Outcomes Stratified by NLR
| Overall | Q1 (NLR<3.68) | Q2 (3.68≤NLR<6.89) | Q3 (6.89≤NLR<12.14) | Q4 (12.14≤NLR) | P trend | ||||
|---|---|---|---|---|---|---|---|---|---|
| 30-day follow-up | 594 | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | ||
| mRS≥3 (3–6) | 387 (65.15) | ||||||||
| Crude | Ref. | 0.91 (0.57–1.44) | 0.68 | 1.47 (0.92–2.35) | 0.11 | 3.32 (1.96–5.64) | <0.01 | <0.01 | |
| Adjusted | Ref. | 0.88 (0.49–1.59) | 0.67 | 1.24 (0.66–2.32) | 0.51 | 2.37 (1.17–4.83) | 0.02 | <0.01 | |
| Disabled (3–5) | 267 (56.33) | ||||||||
| Crude | Ref. | 1.02 (0.62–1.67) | 0.94 | 1.47 (0.89–2.45) | 0.14 | 2.97 (1.69–5.22) | <0.01 | <0.01 | |
| Adjusted | Ref. | 0.82 (0.44–1.54) | 0.54 | 1.10 (0.56–2.13) | 0.79 | 2.21 (1.05–4.65) | 0.04 | <0.01 | |
| Death | 120 (20.20) | ||||||||
| Crude | Ref. | 0.65 (0.34–1.24) | 0.19 | 1.18 (0.66–2.12) | 0.57 | 2.12 (1.22–3.66) | <0.01 | <0.01 | |
| Adjusted | Ref. | 0.64 (0.30–1.39) | 0.26 | 0.78 (0.38–1.60) | 0.05 | 0.95 (0.47–1.90) | 0.88 | 0.62 | |
| 3-month follow-up | |||||||||
| mRS≥3 (3–6) | 348 (58.59) | ||||||||
| Crude | Ref. | 0.96 (0.61–1.51) | 0.86 | 1.44 (0.91–2.28) | 0.12 | 3.72 (2.24–6.18) | <0.01 | <0.01 | |
| Adjusted | Ref. | 1.00 (0.54–1.84) | 0.99 | 1.15 (0.61–2.18) | 0.67 | 2.83 (1.38–5.77) | <0.01 | <0.01 | |
| Disabled (3–5) | 221 (47.32) | ||||||||
| Crude | Ref. | 1.12 (0.68–1.86) | 0.66 | 1.42 (0.85–2.38) | 0.18 | 3.46 (1.98–6.05) | <0.01 | <0.01 | |
| Adjusted | Ref. | 0.92 (0.47–1.80) | 0.81 | 0.99 (0.50–1.99) | 0.99 | 2.77 (1.28–5.98) | <0.01 | <0.01 | |
| Death | 127 (21.38) | ||||||||
| Crude | Ref. | 0.66 (0.35–1.24) | 0.19 | 1.28 (0.72–2.25) | 0.40 | 2.15 (1.25–3.69) | <0.01 | <0.01 | |
| Adjusted | Ref. | 0.65 (0.31–1.38) | 0.26 | 0.89 (0.44–1.80) | 0.75 | 0.99 (0.50–1.96) | 0.97 | 0.61 | |
| 1-year follow-up | |||||||||
| mRS≥3 (3–6) | 304 (51.18) | ||||||||
| Crude | Ref. | 0.73 (0.46–1.16) | 0.18 | 1.37 (0.87–2.16) | 0.18 | 3.03 (1.88–4.91) | <0.01 | <0.01 | |
| Adjusted | Ref. | 0.59 (0.32–1.08) | 0.09 | 1.01 (0.55–1.86) | 0.96 | 1.75 (0.91–3.34) | 0.09 | 0.01 | |
| Disabled (3–5) | 161 (35.70) | ||||||||
| Crude | Ref. | 0.68 (0.38–1.21) | 0.19 | 1.38 (0.80–2.38) | 0.25 | 2.86 (1.63–5.01) | <0.01 | <0.01 | |
| Adjusted | Ref. | 0.34 (0.16–0.72) | <0.01 | 0.83 (0.41–1.65) | 0.59 | 1.61 (0.77–3.37) | 0.21 | 0.02 | |
| Death | 143 (24.07) | ||||||||
| Crude | Ref. | 0.87 (0.49–1.55) | 0.64 | 1.21 (0.70–2.10) | 0.50 | 2.07 (1.22–3.50) | <0.01 | <0.01 | |
| Adjusted | Ref. | 0.96 (0.48–1.90) | 0.90 | 0.88 (0.45–1.74) | 0.72 | 0.99 (0.51–1.92) | 0.98 | 0.66 | |
Note: Adjusted for age, sex, smoking, GCS at first admission, NIHSS at first admission, hematoma volume at first admission and SBP.
Abbreviations: NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale.